Search results for "Deme"

showing 10 items of 883 documents

Determinants of Quality of Life According to Cognitive Status in Parkinson’s Disease

2020

Background: Quality of life (QoL) was worse in Parkinson's disease patients with mild cognitive impairment (PD-MCI) or dementia (PDD) than PD patients with normal cognition (PD-NC). The aim of this study was to investigate and compare the potential heterogeneous determinants of QoL in PD patients with different cognitive statuses. Methods: We recruited 600 PD patients, including 185 PD-NC patients, 336 PD-MCI patients and 79 PDD patients, in this cross-sectional study. All patients completed the QoL assessment by the 39-item Parkinson's Disease Questionnaire (PDQ-39), as well as clinical evaluations and neuropsychological tests. The determinants of the QoL were analysed by multiple stepwise…

0301 basic medicineAgingmedicine.medical_specialtyParkinson's diseaseCognitive NeuroscienceDiseasebehavioral disciplines and activitieslcsh:RC321-57103 medical and health sciences0302 clinical medicinemild cognitive impairmentQuality of lifeRating scalemental disordersmedicineDementialcsh:Neurosciences. Biological psychiatry. NeuropsychiatryDepression (differential diagnoses)Original Researchbusiness.industryNeuropsychologyCognitiondeterminantsmedicine.diseasehumanitiesnervous system diseases030104 developmental biologyquality of lifePhysical therapyParkinson’s diseasebusinesshuman activities030217 neurology & neurosurgeryNeurosciencedementiaFrontiers in Aging Neuroscience
researchProduct

Incidence of Mild Cognitive Impairment and Dementia in Parkinson's Disease: The Parkinson's Disease Cognitive Impairment Study.

2018

Background: Cognitive impairment in Parkinson's disease (PD) includes a spectrum varying from Mild Cognitive Impairment (PD-MCI) to PD Dementia (PDD). The main aim of the present study is to evaluate the incidence of PD-MCI, its rate of progression to dementia, and to identify demographic and clinical characteristics which predict cognitive impairment in PD patients. Methods: PD patients from a large hospital-based cohort who underwent at least two comprehensive neuropsychological evaluations were retrospectively enrolled in the study. PD-MCI and PDD were diagnosed according to the Movement Disorder Society criteria. Incidence rates of PD-MCI and PDD were estimated. Clinical and demographic…

0301 basic medicineAgingmedicine.medical_specialtyParkinson's diseaseCognitive NeuroscienceParkinson's diseasebehavioral disciplines and activitieslcsh:RC321-57103 medical and health sciences0302 clinical medicinemild cognitive impairmentInternal medicinemental disordersMedicineDementiaNeuropsychological assessmentMild cognitive impairment (MCI)lcsh:Neurosciences. Biological psychiatry. NeuropsychiatryOriginal Researchmedicine.diagnostic_testbusiness.industryProportional hazards modelIncidence (epidemiology)Neuropsychologymedicine.diseasenervous system diseasesneuropsychological assessment030104 developmental biologyCohortParkinson’s diseaseincidencebusiness030217 neurology & neurosurgeryNeurosciencedementiaFrontiers in aging neuroscience
researchProduct

Atrial fibrillation and cognitive disorders: An overview on possible correlation

2020

Atrial Fibrillation is the most common cardiac arrhythmia affecting people of all ages, principally the elderly. Cognitive decline and dementia are also prevalent diseases in elderly. The scientific community always showed interest in the possible association between these two pathological entities, both implicating social and economic burden. This has been confirmed by several longitudinal population-based studies. Some studies also revealed that the association between atrial fibrillation and dementia may be not related to history of stroke. Therefore, other pathophysiological mechanisms are likely implicated, so far unclear or undefined. The aim of the present review is to analyse the po…

0301 basic medicineAgingmedicine.medical_specialtyPopulationCognitive declinemacromolecular substancesCognitive disorder03 medical and health sciences0302 clinical medicineInternal medicineAtrial FibrillationmedicineHumansDementiaCognitive Dysfunctioncardiovascular diseasesCognitive declineeducationPathologicalStrokeeducation.field_of_studybusiness.industryCardiac arrhythmiaAtrial fibrillationCognitionmedicine.diseaseStroke030104 developmental biologyCardiologyDementiabusiness030217 neurology & neurosurgeryDevelopmental BiologyMechanisms of Ageing and Development
researchProduct

Magnesium Status in Alzheimer's Disease: A Systematic Review

2016

The interest in poor magnesium (Mg) status as risk factor for Alzheimer's disease (AD) is increasing due to its antioxidant and neuroprotective properties. A systematic PubMed literature search of studies investigating Mg status was undertaken comparing AD to healthy controls (HCs) or patients with medical illness (medical controls [MCs]). Standardized mean differences (SMDs) ± 95% confidence intervals (CIs) were calculated for all outcomes. Of 192 potentially eligible studies, 13 were included (559 patients with AD, 381 HCs, and 126 MCs). Compared to HCs, patients with AD had significantly lower Mg in cerebrospinal fluid (2 studies; SMD = -0.35; P =.02) and in hair (2 studies; SMD = -0.75;…

0301 basic medicineAlzheimer’s disease; aging; dementia; healthy controls; magnesiummedicine.medical_specialtyDiseasemagnesiumbehavioral disciplines and activitiesnot knownNO03 medical and health sciences0302 clinical medicineAlzheimer DiseaseMedical illnessInternal medicinemedicineHumansDementiaRisk factorbusiness.industryGeneral NeuroscienceagingAlzheimer's diseasemedicine.diseaseConfidence intervalPsychiatry and Mental healthClinical Psychology030104 developmental biologyPhysical therapyhealthy controlsaging; Alzheimer's disease; dementia; healthy controls; magnesium; Psychiatry and Mental Health; Geriatrics and Gerontology; Clinical PsychologyGeriatrics and GerontologyAlzheimer's diseasebusinessAlzheimer’s disease030217 neurology & neurosurgerydementia
researchProduct

DNA demethylation caused By 5-Aza-2'-Deoxycytidine induces mitotic alterations and aneuploidy

2016

Aneuploidy, the unbalanced number of chromosomes in a cell, is considered a prevalent form of genetic instability and is largely acknowledged as a condition implicated in tumorigenesis. Epigenetic alterations like DNA hypomethylation have been correlated with cancer initiation/progression. Furthermore, a growing body of evidence suggests the involvement of epigenome-wide disruption as a cause of global DNA hypomethylation in aneuploidy generation. Here, we report that the DNA hypomethylating drug 5-aza-2′-deoxycytidine (DAC), affects the correct ploidy of nearly diploid HCT-116 human cells by altering the methylation pattern of the chromosomes. Specifically, we show that a DAC-induced reduc…

0301 basic medicineAntimetabolites Antineoplastic5-aza-2'-deoxycytidine (DAC); Aneuploidy; Chromosome methylation pattern; Chromosome Section; DNA demethylation; OncologyBlotting WesternAneuploidyMitosisApoptosisBiologymedicine.disease_causeDecitabineReal-Time Polymerase Chain ReactionChromosome Section03 medical and health scienceschromosome methylation patternChromosome instabilitymedicineTumor Cells CulturedHumansEpigeneticsaneuploidyRNA Messenger5-aza-2′-deoxycytidine (DAC)Cell ProliferationGeneticsChromosome AberrationsPloidiesReverse Transcriptase Polymerase Chain ReactionDNA Methylationmedicine.disease5-aza-2'-deoxycytidine (DAC)Gene Expression Regulation NeoplasticResearch Paper: ChromosomeSettore BIO/18 - Genetica030104 developmental biologyDNA demethylationOncologyMicroscopy FluorescenceDNA methylationColonic NeoplasmsCytogenetic AnalysisCancer researchDNA demethylationAzacitidinePloidyCarcinogenesisDNA hypomethylation
researchProduct

Mild Parkinsonian Signs in a Hospital-based Cohort of Mild Cognitive Impairment Types: A Cross-sectional Study

2018

Background:Mild Parkinsonian Signs (MPS) have been associated with Mild Cognitive Impairment (MCI) types with conflicting results.Objective:To investigate the association of individual MPS with different MCI types using logistic ridge regression analysis, and to evaluate for each MCI type, the association of MPS with caudate atrophy, global cerebral atrophy, and the topographical location of White Matter Hyperintensities (WMH), and lacunes.Methods:A cross-sectional study was performed among 1,168 subjects with different types of MCI aged 45-97 (70,52 ± 9,41) years, who underwent brain MRI. WMH were assessed through two visual rating scales. The number and location of lacunes were also rated…

0301 basic medicineApolipoprotein EMalemedicine.medical_specialtyMild parkinsonian signsbehavioral disciplines and activitiesCohort Studies03 medical and health sciencesLateral ventricles0302 clinical medicineAtrophyParkinsonian DisordersRating scaleInternal medicinemental disordersmedicineDementiaHumansCognitive Dysfunctioncaudate atrophyProspective cohort studyAgedglobal cerebral atrophyCerebral atrophyAged 80 and overbusiness.industryMiddle Agedwhite matter hyperintensitiesmedicine.diseaseHyperintensitynervous system diseases030104 developmental biologyCross-Sectional StudiesNeurologyCardiologyFemaleNeurology (clinical)business030217 neurology & neurosurgery
researchProduct

Epilepsy in neuropathologically verified Alzheimer's disease.

2018

Abstract Purpose Subjects with Alzheimer's disease (AD) have been shown to be at a higher risk for epilepsy. The vast majority of the previous studies have not included a full neuropathological examination. Methods The objective of this study was to assess the prevalence of epilepsy and clinicopathological characteristics in a well-defined study group of 64 subjects with AD. We evaluated the clinicopathological findings in 64 subjects (mean age at death 85 ± 8.6 years) from a longitudi-nal study cohort of patients with dementia. Results Eleven out of the 64 subjects (17%) had a history of epilepsy, which is comparable to previous studies. The subjects with AD and epilepsy were significantly…

0301 basic medicineApolipoprotein EMalemedicine.medical_specialtyNeurologyTime FactorsalzheimerAutopsyNeuropathologyDiseaseAlzheimerin tauti03 medical and health sciencesEpilepsyautopsy0302 clinical medicineApolipoproteins EAlzheimer DiseaseInternal medicinemedicinePrevalenceDementiaHumansneurodegenerative diseasesLongitudinal Studiesta515ta316Aged 80 and overEpilepsybusiness.industryneurodegenerationAge FactorsBrainGeneral MedicineAlzheimer's diseasemedicine.diseaseneurodegeneratiiviset sairaudetHospitalization030104 developmental biologyNeurologyruumiinavausCohortFemaleNeurology (clinical)businessepilepsia030217 neurology & neurosurgerydementiaFollow-Up StudiesSeizure
researchProduct

Application of enamel matrix derivative in conjunction with non‐surgical therapy for treatment of moderate to severe periodontitis: A 12‐month, rando…

2020

BACKGROUND Treatment of periodontitis aims to halt progressive bone and attachment loss and regenerate periodontal structures. In this study, the effect of using an enamel matrix derivative (EMD) as an adjunct to non-surgical periodontal therapy (test) versus non-surgical therapy alone (control) was evaluated. METHODS A prospective, split-mouth, multicenter study evaluated scaling and root planing (SRP) with and without EMD in 51 patients presenting with moderate to severe periodontitis (PPD = 5 to 8 mm) in at least 2 pockets per contralateral quadrants within the same arch. The primary outcome variable was change in clinical attachment level (CAL) after 12 months. Secondary variables inclu…

0301 basic medicineBleeding on probingDentistryRoot Planing03 medical and health sciences0302 clinical medicineScaling and root planingPeriodontal Attachment LossEnamel matrix derivativemedicineHumansPeriodontal DebridementProspective StudiesDental EnamelPeriodontitisPeriodontitisbusiness.industry030206 dentistrymedicine.diseaseTreatment Outcome030104 developmental biologyClinical attachment lossDental ScalingPeriodonticsDentin hypersensitivitymedicine.symptombusinessGingival marginJournal of Periodontology
researchProduct

Efficacy and epigenetic interactions of novel DNA hypomethylating agent guadecitabine (SGI-110) in preclinical models of hepatocellular carcinoma.

2016

ABSTRACT Hepatocellular carcinoma (HCC) is a deadly malignancy characterized at the epigenetic level by global DNA hypomethylation and focal hypermethylation on the promoter of tumor suppressor genes. In most cases it develops on a background of liver steatohepatitis, fibrosis, and cirrhosis. Guadecitabine (SGI-110) is a second-generation hypomethylating agent, which inhibits DNA methyltransferases. Guadecitabine is formulated as a dinucleotide of decitabine and deoxyguanosine that is resistant to cytidine deaminase (CDA) degradation and results in prolonged in vivo exposure to decitabine following small volume subcutaneous administration of guadecitabine. Here we found that guadecitabine i…

0301 basic medicineCancer ResearchMethyltransferasesteatohepatitisDecitabineBiologyDecitabineDNA methylation Decitabine guadecitabine hepatocellular carcinoma (HCC) histone macroH2A1 steatohepatitishepatocellular carcinoma (HCC)03 medical and health scienceschemistry.chemical_compoundCDKN2AmedicineEpigeneticsMolecular BiologyneoplasmsDNA methylationGuadecitabineguadecitabinehistone macroH2A1steatohepatitidigestive system diseases3. Good healthDemethylating agent030104 developmental biologychemistryHypomethylating agentDNA methylationCancer researchResearch Papermedicine.drug
researchProduct

Tumor Microenvironment And Epithelial Mesenchymal Transition As Targets To Overcome Tumor Multidrug Resistance

2020

It is well established that multifactorial drug resistance hinders successful cancer treatment. Tumor cell interactions with the tumor microenvironment (TME) are crucial in epithelial-mesenchymal transition (EMT) and multidrug resistance (MDR). TME-induced factors secreted by cancer cells and cancer-associated fibroblasts (CAFs) create an inflammatory microenvironment by recruiting immune cells. CD11b+/Gr-1+ myeloid-derived suppressor cells (MDSCs) and inflammatory tumor associated macrophages (TAMs) are main immune cell types which further enhance chronic inflammation. Chronic inflammation nurtures tumor-initiating/cancer stem-like cells (CSCs), induces both EMT and MDR leading to tumor re…

0301 basic medicineCancer Researchmedicine.medical_treatmentMultidrug resistanceTargeted therapyTargeted therapy0302 clinical medicineCancer-Associated FibroblastsNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsTumor-Associated MacrophagesTumor MicroenvironmentPharmacology (medical)HypoxiaTOR Serine-Threonine KinasesSmall moleculesChemotherapy ; Hypoxia ; Inflammation ; Microenvironment ; Multidrug resistance ; Small molecules ; Targeted therapy.Drug Resistance Multiple3. Good healthDNA DemethylationGene Expression Regulation NeoplasticInfectious DiseasesOncology030220 oncology & carcinogenesisInflammation MediatorsEpithelial-Mesenchymal TransitionStromal cellMicroenvironmentBiologyProinflammatory cytokine03 medical and health sciencesCell Line TumormedicineAnimalsHumansChemotherapyEpithelial–mesenchymal transitionPharmacologyInflammationTumor microenvironmentCancerHypoxia-Inducible Factor 1 alpha Subunitmedicine.diseaseHistone Deacetylase InhibitorsMultiple drug resistanceDisease Models Animal030104 developmental biologyDrug Resistance NeoplasmCancer cellCancer research
researchProduct